These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pertussis in adolescents and adults: should we vaccinate? Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Tormans G; Van Doorslaer E; van Damme P; Clara R; Schmitt HJ Eur J Pediatr; 1998 May; 157(5):395-401. PubMed ID: 9625337 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England. van Hoek AJ; Campbell H; Amirthalingam G; Andrews N; Miller E J Infect; 2016 Jul; 73(1):28-37. PubMed ID: 27108802 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan. Hoshi SL; Seposo X; Okubo I; Kondo M Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878 [TBL] [Abstract][Full Text] [Related]
11. Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the US. Curran D; Terlinden A; Poirrier JE; Masseria C; Krishnarajah G Pediatr Infect Dis J; 2016 May; 35(5):542-7. PubMed ID: 26835971 [TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of immunization against pertussis. Stuart-Harris C Dev Biol Stand; 1979; 43():75-83. PubMed ID: 520687 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of a new acellular vaccine for pertussis in Canada. Iskedjian M; Einarson TR; O'Brien BJ; De Serres JG; Gold R; Gemmill IM; Milkovich N; Rosner A Pharmacoeconomics; 2001; 19(5 Pt 2):551-63. PubMed ID: 11465300 [TBL] [Abstract][Full Text] [Related]
14. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage. Girard DZ Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048 [TBL] [Abstract][Full Text] [Related]
15. Whooping cough and pertussis vaccine: a comparison of risks and benefits in Britain during the period 1968-83. Stewart GT Dev Biol Stand; 1985; 61():395-405. PubMed ID: 3835080 [TBL] [Abstract][Full Text] [Related]
16. The distribution over time of costs and social net benefits for pertussis immunization programs. Girard DZ Int J Health Care Finance Econ; 2010 Mar; 10(1):1-27. PubMed ID: 19294502 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adult pertussis vaccination in Germany. Lee GM; Riffelmann M; Wirsing von Konig CH Vaccine; 2008 Jul; 26(29-30):3673-9. PubMed ID: 18538901 [TBL] [Abstract][Full Text] [Related]
18. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774 [TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of universal pertussis vaccination in Italy. Beutels P; Bonanni P; Tormans G; Canale F; Crovari PC Vaccine; 1999 May; 17(19):2400-9. PubMed ID: 10392622 [TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of pertussis vaccination in adults. Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]